CCN2 and idiopathic pulmonary fibrosis: In IPF, promising results of the PRAISE trial were recently published, which was a phase II randomized trial of Pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, demonstrating attenuation of disease progression (2).